Skip to main content Accessibility help

Osteoprotegerin in pregnant adolescents differs by race and is related to infant birth weight z-score

  • B. Essley (a1), T. McNanley (a2), B. Cooper (a2), A. McIntyre (a2), F. Witter (a3), Z. Harris (a4) and K. O'Brien (a1)...


Osteoprotegerin (OPG) is involved in the regulation of bone turnover, but little is known about this protein during pregnancy or among neonates. We undertook a prospective longitudinal study to identify relationships between OPG, markers of bone turnover and birth outcomes in 155 pregnant adolescents (13–18 years) and their newborns. Maternal blood samples were collected at mid-gestation and at delivery. Cord blood was obtained at delivery. Serum OPG, estradiol and markers of bone formation (osteocalcin) and resorption (N-telopeptide) were assessed in all samples. Placental OPG expression was assessed in placental tissue obtained at delivery. Bone markers and OPG increased significantly from mid-gestation (26.0 ± 3.4 weeks) to delivery (39.3 ± 2.6 weeks). Neonatal OPG was significantly lower, but bone turnover markers were significantly higher than maternal values at mid-gestation and at parturition (P < 0.001). African-American adolescents had higher concentrations of OPG than Caucasian adolescents at mid-gestation (P = 0.01) and delivery (P = 0.04). Gestational age and estradiol were also predictors of maternal OPG at mid-gestation and delivery. OPG concentrations in cord blood were correlated with maternal OPG concentrations and were negatively associated with infant birth weight z-score (P = 0.02) and ponderal index (P = 0.02). In conclusion, maternal OPG concentrations increased across gestation and were significantly higher than neonatal OPG concentrations. Maternal and neonatal OPG concentrations were not associated with markers of bone turnover or placental OPG expression, but neonatal OPG was inversely associated with neonatal anthropometric measures. Additional research is needed to identify roles of OPG during pregnancy.


Corresponding author

*Address for correspondence: Prof. K. O'Brien, Division of Nutritional Sciences, Cornell University, 230 Savage, Ithaca, NY 14853, USA. (Email


Hide All
1.Center for Disease Control and Prevention. Vital signs: teen pregnancy – United States, 1991–2009. Morb Mortal Wkly Rep. 2011; 60, 414420.
2.Felice, ME, Feinstein, RA, Fisher, MM, et al. . Adolescent pregnancy – current trends and issues: 1998 American Academy of Pediatrics Committee on Adolescence, 1998–1999. Pediatrics. 1999; 103, 516520.
3.Black, AJ, Topping, J, Durham, B, Farquharson, RG, Fraser, WD. A detailed assessment of alterations in bone turnover, calcium homeostasis, and bone density in normal pregnancy. J Bone Miner Res. 2000; 15, 557563.
4.Naylor, KE, Iqbal, P, Fledelius, C, Fraser, RB, Eastell, R. The effect of pregnancy on bone density and bone turnover. J Bone Miner Res. 2000; 15, 129137.
5.Cross, NA, Hillman, LS, Allen, SH, Krause, GF, Vieira, NE. Calcium homeostasis and bone metabolism during pregnancy, lactation, and postweaning: a longitudinal study. Am J Clin Nutr. 1995; 61, 514523.
6.Kovacs, CS. Calcium and bone metabolism in pregnancy and lactation. J Clin Endocrinol Metab. 2001; 86, 23442348.
7.Kolthoff, N, Eiken, P, Kristensen, B, Nielsen, SP. Bone mineral changes during pregnancy and lactation: a longitudinal cohort study. Clin Sci (Lond). 1998; 94, 405412.
8.Sowers, M, Wallace, RB, Lemke, JH. Correlates of forearm bone mass among women during maximal bone mineralization. Prev Med. 1985; 14, 585596.
9.Sowers, MF, Scholl, T, Harris, L, Jannausch, M. Bone loss in adolescent and adult pregnant women. Obstet Gynecol. 2000; 96, 189193.
10.Simonet, WS, Lacey, DL, Dunstan, CR, et al. . Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89, 309319.
11.Hofbauer, LC, Heufelder, AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med. 2001; 79, 243253.
12.Hong, JS, Santolaya-Forgas, J, Romero, R, et al. . Maternal plasma osteoprotegerin concentration in normal pregnancy. Am J Obstet Gynecol. 2005; 193, 10111015.
13.Naylor, KE, Rogers, A, Fraser, RB, et al. . Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation. J Clin Endocrinol Metab. 2003; 88, 53615365.
14.Uemura, H, Yasui, T, Kiyokawa, M, et al. . Serum osteoprotegerin/osteoclastogenesis-inhibitory factor during pregnancy and lactation and the relationship with calcium-regulating hormones and bone turnover markers. J Endocrinol. 2002; 174, 353359.
15.Barker, DJ. The origins of the developmental origins theory. J Intern Med. 2007; 261, 412417.
16.Gluckman, PD, Hanson, MA, Cooper, C, Thornburg, KL. Effect of in utero and early-life conditions on adult health and disease. N Engl J Med. 2008; 359, 6173.
17.Cooper, C, Westlake, S, Harvey, N, et al. . Review: developmental origins of osteoporotic fracture. Osteoporos Int. 2006; 17, 337347.
18.Schlussel, MM, Dos, SV, Kac, G. Birth weight and adult bone mass: a systematic literature review. Osteoporos Int. 2010; 21, 19811991.
19.Kramer, MS, Platt, RW, Wen, SW, et al. . A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics. 2001; 108, E35E42.
20.Gundberg, CM, Cole, DE, Lian, JB, Reade, TM, Gallop, PM. Serum osteocalcin in the treatment of inherited rickets with 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab. 1983; 56, 10631067.
21.Andreasyan, K, Ponsonby, AL, Dwyer, T, et al. . Higher maternal dietary protein intake in late pregnancy is associated with a lower infant ponderal index at birth. Eur J Clin Nutr. 2007; 61, 498508.
22.Lonergan, M, Aponso, D, Marvin, KW, et al. . Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, and the soluble receptor osteoprotegerin in human gestational membranes and amniotic fluid during pregnancy and labor at term and preterm. J Clin Endocrinol Metab. 2003; 88, 38353844.
23.Briana, DD, Boutsikou, M, Baka, S, et al. . Circulating osteoprotegerin and sRANKL concentrations in the perinatal period at term. The impact of intrauterine growth restriction. Neonatology. 2009; 96, 132136.
24.Dimitri, P, Wales, JK, Bishop, N. Adipokines, bone-derived factors and bone turnover in obese children; evidence for altered fat-bone signalling resulting in reduced bone mass. Bone. 2011; 48, 189196.
25.Specker, B. Nutrition influences bone development from infancy through toddler years. J Nutr. 2004; 134, 691S695S.
26.Namgung, R, Tsang, RC. Factors affecting newborn bone mineral content: in utero effects on newborn bone mineralization. Proc Nutr Soc. 2000; 59, 5563.
27.Raman, L, Rajalakshmi, K, Krishnamachari, KA, Sastry, JG. Effect of calcium supplementation to undernourished mothers during pregnancy on the bone density of the bone density of the neonates. Am J Clin Nutr. 1978; 31, 466469.
28.Viljakainen, HT, Korhonen, T, Hytinantti, T, et al. . Maternal vitamin D status affects bone growth in early childhood – a prospective cohort study. Osteoporos Int. 2011; 22, 883891.
29.Javaid, MK, Crozier, SR, Harvey, NC, et al. . Maternal vitamin D status during pregnancy and childhood bone mass at age 9 years: a longitudinal study. Lancet. 2006; 367, 3643.
30.Dennison, EM, Arden, NK, Keen, RW, et al. . Birthweight, vitamin D receptor genotype and the programming of osteoporosis. Paediatr Perinat Epidemiol. 2001; 15, 211219.
31.Antoniades, L, MacGregor, AJ, Andrew, T, Spector, TD. Association of birth weight with osteoporosis and osteoarthritis in adult twins. Rheumatology (Oxford). 2003; 42, 791796.
32.Dai, Y, Shen, L. Relationships between serum osteoprotegerin, matrix metalloproteinase-2 levels and bone metabolism in postmenopausal women. Chin Med J (Engl). 2007; 120, 20172021.
33.Jiang, LS, Zhang, ZM, Jiang, SD, Chen, WH, Dai, LY. Differential bone metabolism between postmenopausal women with osteoarthritis and osteoporosis. J Bone Miner Res. 2008; 23, 475483.
34.Ohwada, R, Hotta, M, Sato, K, Shibasaki, T, Takano, K. The relationship between serum levels of estradiol and osteoprotegerin in patients with anorexia nervosa. Endocr J. 2007; 54, 953959.
35.Hofbauer, LC, Khosla, S, Dunstan, CR, et al. . Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 1999; 140, 43674370.
36.Li, Q, Yu, K, Tian, X, et al. . 17beta-estradiol overcomes human myeloma RPMI8226 cell suppression of growth, ALP activity, and mineralization in rat osteoblasts and improves RANKL/OPG balance in vitro. Leuk Res. 2009; 33, 12661271.
37.Looker, AC, IIIMelton, LJ, Harris, T, et al. . Age, gender, and race/ethnic differences in total body and subregional bone density. Osteoporos Int. 2009; 20, 11411149.
38.Emery, JG, McDonnell, P, Burke, MB, et al. . Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998; 273, 1436314367.
39.Vitovski, S, Phillips, JS, Sayers, J, Croucher, PI. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem. 2007; 282, 3160131609.
40.Collin-Osdoby, P, Rothe, L, Anderson, F, et al. . Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem. 2001; 276, 2065920672.
41.Corallini, F, Celeghini, C, Rimondi, E, et al. . TRAIL down-regulates the release of osteoprotegerin (OPG) by primary stromal cells. J Cell Physiol. 2011; 226, 22792286.
42.Anum, EA, Springel, EH, Shriver, MD, IIIStrauss, JF. Genetic contributions to disparities in preterm birth. Pediatr Res. 2009; 65, 19.
43.Velez, DR, Fortunato, SJ, Morgan, N, et al. . Patterns of cytokine profiles differ with pregnancy outcome and ethnicity. Hum Reprod. 2008; 23, 19021909.


Osteoprotegerin in pregnant adolescents differs by race and is related to infant birth weight z-score

  • B. Essley (a1), T. McNanley (a2), B. Cooper (a2), A. McIntyre (a2), F. Witter (a3), Z. Harris (a4) and K. O'Brien (a1)...


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed